SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · Spero Therapeutics reported Q2 2026 financial results, highlighting a…

Spero Therapeutics, Inc. · PRESS-RELEASE filed Aug 12, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 12, 2026 at 16:01 ET

Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compared to a net loss of $10.7 million in the same period last year. The company ended the quarter with $60.7 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The results are largely neutral for a clinical-stage biotech with no approved products, as the focus remains on pipeline development rather than financial performance.

  • Net loss of $11.0 million for Q2 2026, compared to $10.7 million in Q2 2025.
  • Cash, cash equivalents, and marketable securities of $60.7 million as of June 30, 2026.
  • Research and development expenses were $7.5 million for Q2 2026, down from $8.5 million in Q2 2025.
  • General and administrative expenses were $4.2 million for Q2 2026, compared to $4.0 million in Q2 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access